News | News By Subject | News by Disease News By Date | Search News

Neutropenia News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Novartis AG (NVS)'s Sandoz Bags Approval for First Biosimilar to be Sold in the U.S.     3/9/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Amgen (AMGN) Release: Phase 3 Study Published In The Journal Of Clinical Oncology Shows First-Cycle Administration Of Neulasta Significantly Lowers Incidence Of Neutropenia With Related Fever And Hospitalization     2/28/2005
Amgen (AMGN) Release: Phase 3 Study Shows Majority Of Neutropenia With Related Fever And Hospitalization Occurs In First Treatment Cycle For Breast Cancer Patients Not Receiving Neulasta     12/13/2004
Maxygen, Inc. (MAXY) And Rentschler Biotechnologie GmbH & Co. Sign Agreement To Manufacture Novel G-CSF     9/9/2004

News from Around the Web
No News Posted on that date

Press Releases
U.S. FDA Accepts Biologics License Application (BLA) For Mylan (MYL) And BioCon (BIOCON.NS)'s Proposed Biosimilar Pegfilgrastim For Review     2/16/2017
BeyondSpring Pharmaceuticals Release: FDA Accepts Company IND Application For Plinabulin For The Prevention Of Chemotherapy-Induced Neutropenia     1/24/2017
BeyondSpring Pharmaceuticals Clinical Data On Neutropenia Mitigation With Plinabulin To Be Presented At 2016 American Society of Hematology Annual Meeting     11/4/2016
ASCO Selects BeyondSpring Abstract On Neutropenia Mitigation With Plinabulin Use For Publication     5/27/2016
New Patent Issued To Cantex Pharmaceuticals For Its Lead Product Candidate In The Treatment Of Thrombocytopenia And Neutropenia     3/2/2016
Nektar Therapeutics (NKTR) Announces Receipt Of $40 Million Milestone Payment Resulting From First Commercial Sale Of MOVENTIG (naloxegol) Tablets In Major European Market     9/1/2015
Allergan (AGN) Confirms Generic Noxafil Patent Challenge     8/12/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia     4/8/2013
Ligand Pharmaceuticals Inc. (LGND) Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology     12/13/2011
BioGeneriX AG and Neose Technologies, Inc. (NTEC) Initiate Phase 2 Trial for GlycoPEG-GCSF     6/23/2008
Cleveland Biolabs Inc. (CBLI) Achieves Recovery From Neutropenia and Thrombocytopenia in Primates 48 Hours Post-Irradiation With Protectan CBLB502     12/4/2007
Merck & Co., Inc. (MRK) Study Presented on Use of CANCIDAS(R) (caspofungin acetate) as Empirical Therapy of Suspected Invasive Fungal Infections in Pediatric Patients with Persistent Fever and Neutropenia     9/17/2007
Neose Technologies, Inc. (NTEC) Announces BioGeneriX AG's Initiation Of Phase I Trial Of GlycoPEG-GCSF     11/9/2006
Amgen (AMGN) Release: Large Community-Based Clinical Trial In Older Cancer Patients Suggests Benefits Of Neulasta In First And Subsequent Cycles Of Chemotherapy     5/16/2005
Cellerant Therapeutics, Inc. Announces Publication Confirming Activity Of Myeloid Progenitor Cells In Mouse Model Of Chemotherapy-Induced Neutropenia     12/7/2004